U.S. Markets closed

PTC Therapeutics CFO: Positive News on Translarna Just the Start


PTC Therapeutics received a positive opinion from a European regulator in May for its Duchenne muscular dystrophy (DMD) treatment Translarna and conditional approval in Europe is expected this summer, said the company's CFO Shane Kovacs. Kovacs said the company, which has seen its shares nearly double in price since the May announcement, is currently enrolling a large-scale, placebo-controlled, confirmatory Phase 3 trial for Translarna in nonsense mutation DMD. Furthermore, he said PTC initiated a confirmatory Phase 3 study of Translarna in nonsense mutation cystic fibrosis.